Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid Tumours

Phase I, open study to assess the effect of rifampicin, a marketed drug, on how the body handles the experimental drug cediranib in patients with advanced cancer.

Inclusion Criteria:

• Written informed consent
• Prostate cancer), which is refractory to standard therapies or for which no standard therapy exists.
• Estimated life expectancy of at least 8 weeks
• WHO performance status (PS) 0-2.

Exclusion Criteria:

• Unstable brain/meningeal metastases
• Biochemistry/haematology results outside of required ranges
• History of significant GI impairment
• Inadequate bone marrow reserve